Abstract
Background: Lung function tests are a pioneer step in the evaluation of patients with hemopathy undergoing stem cell transplantation. The pretransplant lung function score (PLS) is a predicting factor of posttransplant pulmonary complications (e.g., early respiratory failure).
Aim: To test whether the PLS is depending on the hemopathy type.
Materiel and methods: This was a retrospective study including patients with malignant hemopathy who underwent plethysmography and diffusing capacity of carbon monoxide (DLCO) prior to stem cell transplantation. The PLS was calculated based on the FEV1 and DLCO in percent predicted (Parimon T, et al. Am J Respir Crit Care Med 2005; 172:384–390).
Results: A total of 25 patients were included where 13 (48%) were males. The mean age was 46±13 years. The means±SD of forced expiratory volume in 1s (FEV1) and DLCO were 88±15 et 112±23 % predicted, respectively. The PLS was normal, mildly decreased and moderately decreased in 16 (64%), 7 (28%) et 2 (8%) patients, respectively. Our population was divided into two groups: G1 with normal PLS (n=16) and G2 with decreased PLS (n=9). Multiple myeloma (MM) was the most frequent hemopathy type in both groups. There was no statistically significant difference between G1 and G2 when compared by hemopathy type (MM, leukemia, lymphoma and others) (Chi² test, p>0.05). There was no relationship between the PLS and the hemopathy type.
Measurements and Main Results: The pretransplant lung function score was not influenced by the hemopathy type.
Footnotes
Cite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3300.
This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2021